[HTML][HTML] … therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study
B Liu, X Liu, H Xing, H Ma, Z Lv, Y Zheng… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
… Thus, in this study, we aimed to evaluate the efficacy and … of this study are compared with
those of previous studies in … , it is accompanied by serious adverse events (AEs). Therefore, …
those of previous studies in … , it is accompanied by serious adverse events (AEs). Therefore, …
The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
H Xiang, D Danna, C Xuefei, J Zhao, G Jin - Anti-Cancer Drugs, 2024 - journals.lww.com
… of advanced non small cell lung cancer (NSCLC). Some … patients experienced a grade 3
or higher adverse event, no … -TKIs were participated in our retrospective analysis. Of these …
or higher adverse event, no … -TKIs were participated in our retrospective analysis. Of these …
[HTML][HTML] Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
HS Li, JL Li, X Yan, HY Xu, LQ Zhou… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
… the efficacy of dacomitinib, we retrospectively analyzed 18 … All patients had grade 1–2 adverse
effects (AEs), but no grade … significant differences were found in grade 1–3 AEs between …
effects (AEs), but no grade … significant differences were found in grade 1–3 AEs between …
[HTML][HTML] … efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study
C Zhou, Z Wang, C Fu, H Tao, C Liu - Annals of Translational …, 2023 - ncbi.nlm.nih.gov
… (PFS) and grade 3–5 adverse events (AEs), while the … -world retrospective study had a
unique advantage compared with … positive patients could not obtain appreciable benefit from PD…
unique advantage compared with … positive patients could not obtain appreciable benefit from PD…
[HTML][HTML] Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysis
L Zhao, Z Zhao, X Yan, F Wu, N Sun, R Guo… - International Journal of …, 2024 - hindawi.com
… of treatment were made in terms of efficacy and safety. Adverse events and responses
were … Tokunaga et al., “A phase II study of gefitinib with concurrent thoracic radiotherapy in …
were … Tokunaga et al., “A phase II study of gefitinib with concurrent thoracic radiotherapy in …
… in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer …
YH Huang, KH Hsu, JS Tseng, TY Yang, KC Chen… - Targeted Oncology, 2022 - Springer
… We retrospectively analyzed patients with advanced and … study in Taiwan to compare the
difference in clinical efficacy … Finally, because previous trials had displayed the adverse events …
difference in clinical efficacy … Finally, because previous trials had displayed the adverse events …
[HTML][HTML] … almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
X Fang, Y Xiang, K Lu - Frontiers in Oncology, 2023 - ncbi.nlm.nih.gov
… effects and adverse events of the two groups were compared … significantly prolonged PFS
compared with gefitinib (mPFS: … In this study, we retrospectively analysed the efficacy of 68 …
compared with gefitinib (mPFS: … In this study, we retrospectively analysed the efficacy of 68 …
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
T Hori, K Yamamoto, T Ito, S Ikushima, T Omura… - Investigational New …, 2024 - Springer
… reduction is often required due to adverse events (AEs). This … This was a retrospective study
including patients with EGFR-… efficacy of this study compared with previous reports. In this …
including patients with EGFR-… efficacy of this study compared with previous reports. In this …
Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study
T Zhou, S Zhu, Q Xiong, J Gan, J Wei, J Cai, A Liu - BMC cancer, 2023 - Springer
… Myelosuppression was the major adverse event over all IC dose … retrospective study to
evaluate the efficacy and safety of IC in … At present, there is no comparative study on the efficacy of …
evaluate the efficacy and safety of IC in … At present, there is no comparative study on the efficacy of …
… ‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study …
M Inomata, Y Kawashima, R Saito… - Oncology …, 2023 - spandidos-publications.com
… EGFR-TKI therapy because of adverse events, if subsequent … It is difficult to compare the
findings of the present study with … the efficacy of combination therapy with gefitinib plus cytotoxic …
findings of the present study with … the efficacy of combination therapy with gefitinib plus cytotoxic …